Max Rogers

Max Rogers is a highly experienced professional in the field of preclinical genomics and pharmacology, currently serving as Director of Preclinical Genomics at Intellia Therapeutics, Inc. since May 2023. Max leads a team focused on generating critical data packages for regulatory filings related to gene editing and enhances workflow efficiency through automation and software solutions. Prior to this, Max held the position of Associate Director at both Intellia and Moderna, where responsibilities included managing teams, developing project plans, and collaborating with various departments to advance mRNA drug and vaccine projects. Max's earlier career includes significant roles at Kowa Company, Brigham and Women's Hospital CICS, and as a research fellow at Geisel School of Medicine at Dartmouth, with a focus on target discovery and neurodegeneration research. The academic background consists of a PhD in Biochemistry from Geisel School of Medicine and extensive research experience at reputable institutions.